av Øivind Enger | mai 28, 2020 | News
Vaccibody announces First Patient Dosed in its VB C-02 trial; a multi-centre, open-label Phase II clinical trial testing a combination of Vaccibody’s VB10.16, a targeted DNA vaccine, and Roche’s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in...
av Øivind Enger | mai 20, 2020 | News
US biopharmaceutical company Rallybio has announced that they have completed a USD 145 mill Series B financing to advance the company’s portfolio of product candidates targeting devastating rare diseases. Rallybio’s lead candidate is RLYB211 that the...
av Øivind Enger | mai 5, 2020 | News
BerGenBio today announced that the company has raised mNOK via a private placement that took place via an accelerated book building process after close of market on 4 May 2020. Read...
av Øivind Enger | apr 30, 2020 | News
BerGenBio announces that bemcentinib has been selected to be fast-tracked in a new UK national multi-centre randomised Phase 2 clinicial trial initiative that aims to get an early indication of whether bemcentinib could save lives and improve outcomes in the most...
av Øivind Enger | jan 27, 2020 | News
Vaccibody AS announces that it will register on the Norwegian OTC-list (“NOTC”), owned and operated by Oslo Børs, from January 27. Vaccibody will trade under the ticker “VACC”. Read...
